Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Somatostatin Receptor-positive Neuroendocrine Tumor”

52 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 52 results

Early research (Phase 1)Looking for participantsNCT06479811
What this trial is testing

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Who this might be right for
Head and Neck TumorsKidney CancersSmall Cell Lung Cancers+3 more
National Cancer Institute (NCI) 120
Large-scale testing (Phase 3)Active Not RecruitingNCT04919226
What this trial is testing

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

Who this might be right for
Neuroendocrine Tumors
ITM Solucin GmbH 259
Early research (Phase 1)Active Not RecruitingNCT04234568
What this trial is testing

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

Who this might be right for
Metastatic Digestive System Neuroendocrine NeoplasmMetastatic Neuroendocrine Tumor
National Cancer Institute (NCI) 31
Testing effectiveness (Phase 2)Looking for participantsNCT03145857
What this trial is testing

Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use

Who this might be right for
Neuroendocrine Tumors
AHS Cancer Control Alberta 1,534
Testing effectiveness (Phase 2)Looking for participantsNCT04665739
What this trial is testing

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Who this might be right for
Advanced Lung Neuroendocrine TumorFunctioning Lung Neuroendocrine TumorLocally Advanced Lung Neuroendocrine Neoplasm+9 more
National Cancer Institute (NCI) 70
Not applicableActive Not RecruitingNCT03691064
What this trial is testing

Post-Authorization Long-Term Safety Study of LUTATHERA

Who this might be right for
Neuroendocrine Tumors
Advanced Accelerator Applications 1,014
Testing effectiveness (Phase 2)Looking for participantsNCT04888481
What this trial is testing

68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors

Who this might be right for
Neuroendocrine Tumors
University of Alberta 600
Early research (Phase 1)Looking for participantsNCT05687123
What this trial is testing

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

Who this might be right for
Metastatic Pancreatic Neuroendocrine TumorPancreatic NeoplasmStage III Pancreatic Neuroendocrine Tumor AJCC v8+2 more
National Cancer Institute (NCI) 24
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05894486
What this trial is testing

Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
Peking University 40
Not applicableActive Not RecruitingNCT02743741
What this trial is testing

Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
University Health Network, Toronto 195
Large-scale testing (Phase 3)Active Not RecruitingNCT06398444
What this trial is testing

A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms

Who this might be right for
Advanced Neuroendocrine Neoplasm
Sinotau Pharmaceutical Group 74
Not applicableApproved For MarketingNCT02705313
What this trial is testing

EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx

Who this might be right for
Neuroendocrine Tumors
Advanced Accelerator Applications
Large-scale testing (Phase 3)Study completedNCT01578239
What this trial is testing

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

Who this might be right for
Carcinoid Tumor of the Small BowelNeuroendocrine Tumour
Advanced Accelerator Applications 231
Early research (Phase 1)Active Not RecruitingNCT05249114
What this trial is testing

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
Providence Health & Services 6
Early research (Phase 1)Looking for participantsNCT04609592
What this trial is testing

Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Stanford University 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT04711135
What this trial is testing

Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

Who this might be right for
Gastroenteropancreatic Neuroendocrine TumorsPheochromocytomaParaganglioma
Advanced Accelerator Applications 11
Not applicableNo Longer AvailableNCT01980732
What this trial is testing

68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors

Who this might be right for
Carcinoid TumorsIslet Cell (Pancreatic NET)Other Neuroendocrine Tumors
Andrei Iagaru
Early research (Phase 1)UnknownNCT04375267
What this trial is testing

177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours

Who this might be right for
Clinical Trial, Phase INeuroendocrine TumorsThymoma+1 more
Vastra Gotaland Region 18
Not applicableStudy completedNCT04946305
What this trial is testing

A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea

Who this might be right for
Somatostatin Receptor-positive GEP-NET
Novartis Pharmaceuticals 89
Testing effectiveness (Phase 2)Active Not RecruitingNCT05724108
What this trial is testing

Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors

Who this might be right for
Metastatic Neuroendocrine Tumor
National Cancer Institute (NCI) 94
Load More Results